ClinicalTrials.gg
RecruitingNCT03052192FAM-CPHUpdated Nov 16, 2026

Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.

An observational study in Aging, Polypharmacy and Malnutrition, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 20 Years to 110 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hvidovre University Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2016; still recruiting 10 years later.
Updated Nov 16, 2026Now RecruitingPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
212
Ages
20 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Malnutrition with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Malnutrition · Denmark.

Started
2016
the only one that year
Observational
7 of 42
2 open now
Registered
17th of 42
by date
Lead sponsor
4 of 42
Hvidovre University Hospital

Among the 42 studies in Malnutrition with a site in Denmark, this one is the only one that started in 2016, is one of 7 observational ones, and was the 17th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

8 of the 42 studies in Malnutrition with a site in Denmark are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 20 Years to 110 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Malnutrition with a site in Denmark, or all of them as a file.
02

Study summary

In this study, the investigators will investigate and characterize acute medical patients in order to optimize patient courses in the acute care departments, especially with regard to polypharmacy and undernourishment. In addition, the investigators will investigate underlying immunological mechanisms of chronic inflammation and biological aging in this population to improve the current knowledge and possibilities for preventing chronic diseases and acute hospitalization.

Read the detailed description

Malnutrition:

Malnutrition among elderly is associated with frailty, including loss of weight, muscle mass, function and quality of life and also with an increased number of hospital admissions. In this study, the investigators aim to describe the development of and the risk factors for malnutrition from admission to 4 weeks after discharge, in addition the investigators wish to characterize the inflammatory state of the malnourished patients.

Inappropriate polypharmacy:

The broad variation among elderly in health, number of chronic diseases, organ function, biological age and function makes the prescription of drugs to this population a very complex task with a high risk of inappropriate medication. 5-30% of all non-elective admissions are caused by inappropriate medications, and many of these are preventable. Therefore, the investigators aim to investigate the feasibility of a pharmacist-geriatrician medication review in the acute care department and the effect on the Medication Appropriateness Index score (MAI-score) .

Chronic inflammation and biological aging:

Chronic inflammation and biological aging promote the development of age-related chronic diseases. There is a large variation in the rate of aging between individuals, in particular among the elderly. This means that the chronological age of a person often does not reflect its true state of aging, the biological age. This challenges the ability to provide appropriate care and to predict responses to treatment and interventions in elderly patients. The underlying causes and mechanisms of biological aging and chronic inflammation are not well understood. There are currently no validated methods for measuring biological age and no measures of chronic inflammation which can be used in an acute setting. Here, the investigators aim to test a novel model for chronic inflammation and investigate the role of the NLRP3 inflammasome, NFkB (nuclear factor kappa light chain enhancer of activated B cells) and miRNAs in biological aging and chronic inflammation.

The study is prospective with 3 groups of study participants: one group is included in the Acute Medical Department and two healthy control groups (one young and one older). The follow-up comprises two predefined examinations and any readmissions at our hospital. Furthermore, participants are followed in the national registries.

03

Conditions studied

  • Aging
  • Polypharmacy
  • Malnutrition
  • Inflammation
  • Emergency Service, Hospital
04

Who can participate

Ages eligible
20 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Three study groups; the FAM group, control group 1 and control group 2

Eligibility criteria

FAM group:

Inclusion Criteria:

  • ≥65 years
  • Acute medical patient
  • Understands and speaks Danish

Exclusion Criteria:

  • Unable to cooperate cognitively
  • Terminal patients
  • Patients in isolation

Control group 1:

Inclusion Criteria:

  • ≥65 years
  • No hospital admissions within the past 2 years

Exclusion Criteria:

  • Acute admissions within the past 2 years
  • Auto-immune diseases
  • Treatment with or biological therapies

Control group 2:

Inclusion Criteria:

  • 20-35 years
  • Caucasian
  • No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)

Exclusion Criteria:

  • Auto-immune or chronic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
212 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • FAM group (n=98)

    ≥65 years. Acutely admitted medical patients. Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup. Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality. If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician. Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size.

  • Control group 1 (n=54)

    ≥65 years. No hospital admissions within the past two years. Matched individually with patients in the FAM group by age, sex, and municipality. Examined at inclusion and 52 weeks after inclusion. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.

  • Control group 2 (n=60)

    20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.) Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples.

06

What researchers measure

Primary outcomes

  1. Eating validation scheme score

    Development in nutritional status and risk factors of malnutrition within the FAM group.

    Time frame: From inclusion to 4 weeks after discharge

  2. MAI score (Medication Appropriateness Index)

    Difference in summed MAI-score per patient. MAI score between inclusion and first follow-up visit (FAM group)

    Time frame: From inclusion to 4 weeks after discharge

  3. NF-kB (Nuclear Factor Kappa light chain enhancer og activated B cells) activity

    The development in NF-kB activity between the groups will be investigated. The association of NF-kB activity with biological ageing-measured by chronic inflammation, and loss of function and cognition-will also be investigated.

    Time frame: From inclusion to 56 weeks after discharge

  4. Chronic inflammation

    Stability and discriminative ability of new model for chronic inflammation (Control group 2)

    Time frame: From inclusion to 4 weeks after inclusion

  5. NLRP3 activity

    Difference in NLRP3 inflammasome activity between groups.

    Time frame: From inclusion to 56 weeks after discharge

Secondary outcomes

  1. Bodyweight (kg)

    Development in bodyweight

    Time frame: From inclusion to 4 and 56 weeks after discharge

  2. Health related Quality of life

    Assessed with EQ-5D-5L(EuroQol-5Dimentions-5Llevels) and mini geriatric depression score

    Time frame: From inclusion to 56 weeks after discharge

  3. Medication under-prescribing

    Assessment of underutilization Index (AOU)

    Time frame: From inclusion to 4 weeks after discharge

  4. Inflammation in malnourished patients

    Characterize the level of inflammation in malnourished patients

    Time frame: 4 weeks after discharge

  5. Functional recovery score

    Assessing activities of daily living to characterize development in physical performance

    Time frame: From inclusion to 56 weeks after discharge

  6. Cystatin C

    Cystatin C

    Time frame: From inclusion to 56 weeks after discharge

  7. Cytokine concentrations

    The concentration of cytokines at baseline and in response to stimulation will be measured

    Time frame: From inclusion to 56 weeks after discharge

  8. Cytometry

    Characterization of immune cell subsets

    Time frame: From inclusion to 56 weeks after discharge

  9. miRNA

    Levels of miRNA will be measured, and their association with NF-kB activity and biological ageing will be investigated.

    Time frame: From inclusion to 56 weeks after discharge

  10. NF-kB activation

    The activation of NF-kB in response to stimulation.

    Time frame: From inclusion to 56 weeks after discharge

  11. C-reactive protein (inflammation)

    Difference in inflammation between groups

    Time frame: From inclusion to 56 weeks after discharge

  12. Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml)

    The plasma level of suPAR is a measure of inflammation and can be used to assess the difference in inflammation between groups

    Time frame: From inclusion to 56 weeks after discharge

  13. Frequency of physicians' acceptance of suggested changes in medications

    Frequency of physicians' acceptance of suggested changes in medications

    Time frame: At inclusion and at 4 weeks after discharge in the FAM group

Other outcomes

  1. Sit-to-stand test

    Development in physical performance

    Time frame: From inclusion to 56 weeks after discharge

  2. Cognitive functional ability

    Orientation memory concentration, mini mental state examination, Hopkins verbal learning test, trail making test, digit symbol substitution test

    Time frame: From inclusion to 56 weeks after discharge

  3. Waist circumference (cm)

    Waist circumference (cm)

    Time frame: From inclusion to 56 weeks after discharge

  4. Handgrip strength (kg) of dominant hand

    Development in physical performance

    Time frame: From inclusion to 56 weeks after discharge

  5. Habitual 4 m gait speed (m/s)

    Development in physical performance

    Time frame: From inclusion to 56 weeks after discharge

  6. Plasma and serum concentrations of admission blood samples

    Routinely analyzed physiological biomarkers measured in plasma and serum

    Time frame: From inclusion to 56 weeks after discharge

  7. Blood concentration of cholesterol and triglycerides

    Blood concentration of cholesterol and triglycerides

    Time frame: From inclusion to 56 weeks after discharge

  8. Blood concentration of metabolic markers

    Measurement of insulin, blood glucose, and HbA1c

    Time frame: From inclusion to 56 weeks after discharge

  9. Plasma concentration of active drug substances

    Plasma concentration of active drug substances

    Time frame: From inclusion to 56 weeks after discharge

  10. CMV-IgG (Cytomegalovirus-immunoglobulin G)

    Cytomegalovirus IgG titer

    Time frame: From inclusion to 56 weeks after discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Nielsen RL, Bornaes O, Iversen E, Strejby Christensen LW, Kallemose T, Jawad B, Rasmussen HH, Munk T, Lund TM, Andersen O, Houlind MB, Leegaard Andersen A, Tavenier J. Growth differentiation factor 15 (GDF15) levels are associated with malnutrition in acutely admitted older adults. Clin Nutr. 2024 Aug;43(8):1685-1693. doi: 10.1016/j.clnu.2024.06.005. Epub 2024 Jun 7. PubMed 38879915 ↗
  • Bornaes O, Andersen AL, Houlind MB, Kallemose T, Tavenier J, Aharaz A, Nielsen RL, Jorgensen LM, Beck AM, Andersen O, Petersen J, Pedersen MM. Mild Cognitive Impairment Is Associated with Poorer Nutritional Status on Hospital Admission and after Discharge in Acutely Hospitalized Older Patients. Geriatrics (Basel). 2022 Sep 10;7(5):95. doi: 10.3390/geriatrics7050095. PubMed 36136804 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2016 (actual). Primary completion is estimated for Oct 2031, 179 months after the start.

Of 175 non-industry observational studies under Malnutrition, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 179 months is above that.

Counting every sponsor, half of 187 studies reached it within 21 months; a quarter within 11 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2019 → Oct 2031 and completion Dec 2019 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2017
First posted
Feb 14, 2017
StartActual
Nov 2016
Primary completionEst.
Oct 2031was Dec 2019
CompletionEst.
Oct 2031was Dec 2019
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Amager & Hvidovre Hospital · Hvidovre, Denmark
Show 1 removed
  • Amager & Hvidovre Hospital · Hvidovre, Denmark
Nov 16, 2026
Primary completion
Dec 2019→Oct 2031
Nov 16, 2026
Study completion
Dec 2019→Oct 2031
Nov 16, 2026
Secondary outcomes
1 edited, 5 description edited
What changed in the outcomes
  • EditedHealth related Quality of lifeTime frame: From inclusion to 56 weeks after discharge
  • DescriptionCystatin C: how it is measured was reworded
  • DescriptionFrequency of physicians' acceptance of suggested changes in medications: how it is measured was reworded
  • Descriptionother outcomeBlood concentration of cholesterol and triglycerides: how it is measured was reworded
  • Descriptionother outcomePlasma concentration of active drug substances: how it is measured was reworded
  • Descriptionother outcomeWaist circumference (cm): how it is measured was reworded
Nov 16, 2026
Contact
Study contact now listed: added a•••@regionh.dk · •••6719. See the current contact
Nov 16, 2026
Sponsor
Collaborators removed: Clinical Research Centre
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Status unknown→Recruiting
    1 site added, 1 site removed
    Show site
    • Amager & Hvidovre Hospital · Hvidovre, Denmark
    Show 1 removed
    • Amager & Hvidovre Hospital · Hvidovre, Denmark
    Primary completion Dec 2019→Oct 2031
    Study completion Dec 2019→Oct 2031
    Secondary outcomes 1 edited, 5 description edited
    What changed in the outcomes
    • EditedHealth related Quality of lifeTime frame: From inclusion to 56 weeks after discharge
    • DescriptionCystatin C: how it is measured was reworded
    • DescriptionFrequency of physicians' acceptance of suggested changes in medications: how it is measured was reworded
    • Descriptionother outcomeBlood concentration of cholesterol and triglycerides: how it is measured was reworded
    • Descriptionother outcomePlasma concentration of active drug substances: how it is measured was reworded
    • Descriptionother outcomeWaist circumference (cm): how it is measured was reworded
    Sponsor Collaborators removed: Clinical Research Centre
    Contact Study contact now listed: added a•••@regionh.dk · •••6719. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03052192
Collaborators
Lundbeck Foundation, Region Hovedstadens Apotek
Responsible party
Ove Andersen (Head of Department of Clinical Research, Hvidovre University Hospital) — Principal investigator
First posted
Feb 14, 2017
Start date
Nov 2016
Primary completion
Oct 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Aino L. Andersen, MSc
Contact
aino.leegaard.andersen@regionh.dk
004538626719
Ove Andersen, MD, PhD
study chair · Hvidovre University Hospital
Morten B. Houlind, MSc
principal investigator · Hvidovre University Hospital
Juliette Tavenier, MSc
principal investigator · Hvidovre University Hospital
Line JH Rasmussen, MSc
principal investigator · Hvidovre University Hospital
Aino L Andersen, MSc
principal investigator · Hvidovre University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion